Investigation into Proposed Sale of Paragon 28, Inc. to Zimmer Biomet Holdings, Inc.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are conducting an investigation into the proposed sale of Paragon 28, Inc. (FNA) to Zimmer Biomet Holdings, Inc. (ZBH). This investigation comes in response to concerns regarding the proposed transaction’s fairness to Paragon 28 shareholders.
Terms of the Proposed Transaction
Under the terms of the proposed sale, Paragon 28 shareholders will receive $13.00 in cash per share. In addition to this cash payment, shareholders will also receive a non-tradeable contingent value right (CVR). This CVR entitles the holder to receive up to $1.00 per share in cash if certain revenue milestones are met.
Investigation Details
KSF is encouraging Paragon 28 shareholders who are concerned about the proposed sale to contact the firm. The investigation focuses on whether the proposed transaction undervalues the company and whether Paragon 28 shareholders will be receiving fair value for their shares. KSF is also examining the potential impact of any conflicts of interest on the Paragon 28 board of directors and management.
Impact on Individual Shareholders
If you are a Paragon 28 shareholder and believe that the proposed sale price undervalues the company, or if you have concerns about the potential conflicts of interest involved in the transaction, you may want to consider contacting KSF to discuss your legal rights. As a shareholder, you have a right to seek the maximum value for your shares.
Impact on the World
The proposed sale of Paragon 28 to Zimmer Biomet Holdings could have far-reaching implications for the medical device industry. Paragon 28 is a leading provider of orthopedic and sports medicine products, while Zimmer Biomet is a global leader in musculoskeletal healthcare. The merger could lead to increased competition and innovation in the industry, as well as potential cost savings and operational efficiencies.
Conclusion
The proposed sale of Paragon 28 to Zimmer Biomet Holdings is a significant transaction that could have a significant impact on both individual shareholders and the medical device industry as a whole. If you are a Paragon 28 shareholder and have concerns about the proposed sale, or if you have information that may be relevant to the investigation, you may want to consider contacting KSF to discuss your legal rights. As the investigation progresses, we will continue to provide updates on any developments related to this transaction.
- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. and KSF are investigating the proposed sale of Paragon 28 to Zimmer Biomet Holdings.
- Shareholders will receive $13.00 in cash per share and a non-tradeable CVR entitling them to up to $1.00 per share if revenue milestones are met.
- KSF is investigating whether the proposed transaction undervalues Paragon 28 and whether shareholders will receive fair value for their shares.
- Individual Paragon 28 shareholders who have concerns about the proposed sale or believe they have relevant information may want to contact KSF.
- The merger could lead to increased competition and innovation in the medical device industry.
